16 September 2026 editorial review · Trial
TrialNet platform: teplizumab vs low-dose ATG to delay stage-3 T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: September 9 registry andTrialNet ASCEND page now agree recruiting. Corrected target 60 and DPTRS 6-month surrogate endpoint, not observed clinical onset prevention.
Registry: NCT07216391; RECRUITING; updated 2026-09-09; enrollment 60 (ESTIMATED); results not posted.
Endpoint comparison: Change in DPTRS at six months (6 months after completion of study drug administration).
Sources for this record: NCT07216391: TrialNet platform: teplizumab vs low-dose ATG to delay stage-3 T1D (registry); ATG and Teplizumab Comparative Prevention Study (ASCEND T1D) (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.